NCT05799690Fut, nem toboroz
Comparison of Different Rehabilitation Protocols in Parkinson's Disease With Postural Instability and Gait Disorders
Multiparametric Biomarkers to Predict the Response to Different Protocols of Motor-cognitive Rehabilitation in Parkinson's Disease Subjects With Postural Instability and Gait Disorders
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. márc. 9.
Rövid összefoglaló (regiszter, angolul)
The aim of the study is to compare the effects of 2 different dosages and modalities of motor-cognitive rehabilitation in Parkinson's disease with postural instability and gait disorders (PD-PIGD) on clinical features, neuroimaging and blood-based biomarkers at short-term (2 months) and long-term (7 months) follow-up. Fifty subjects with PD-PIGD will be randomized in 2 training groups: DUAL-TASK+AOT-MI and the DUAL-TASK groups. The DUAL-TASK+AOT-MI group will perform a dual-task gait/balance training consisting of action observation training (AOT) and motor imagery (MI) combined with practicing the observed-imagined exercises; DUAL-TASK group will perform the same exercises combined with watching landscape videos. The training will last 6 weeks, 3 times/week, 1 hour per session. Before and after training (W6), all the patients will undergo neurological, gait/balance, cognitive/behavioral, magnetic resonance imaging (MRI) and serum biomarkers evaluations. Neurological, gait/balance, cognitive/behavioral assessments and serum biomarkers will be also repeated at the 14-week follow-up (W14) to assess maintenance of results. Patients of both DUAL-TASK+AOT-MI and DUAL-TASK groups will be further randomized to repeat the training (6 weeks, 3 times/week, 1 hour each session) starting at W14 (DUAL-TASK+AOT-MI_DOUBLE and DUAL-TASK_DOUBLE groups). After six weeks (W20) all the subjects repeating the training will be evaluated (neurological, gait/balance, cognitive/behavioral assessments). At 28-week follow-up (W28), the whole sample of patients will be assessed with neurological, gait/balance, cognitive/behavioral, MRI and serum biomarkers evaluations. All MRI scans will be acquired at least 12 hours after last dopaminergic therapy administration to mitigate the pharmacological effects on neural activity. Twenty age- and sex-matched healthy controls will be recruited to perform gait/balance and cognitive/behavioral assessments, blood sample and brain MRI acquisition at baseline. The secondary aims of the study are to define the neuroimaging and blood-based biomarkers of PD-PIGD patients presenting different clinical features (e.g. presence of mild cognitive impairment, freezing of gait, falls and mood disturbances) and to evaluate the role of blood-based and neuroimaging biomarkers, together with clinical characteristics, in predicting the response to different dosages of rehabilitation in PD-PIGD throughout the development of a machine-learning algorithm.
- Állapot (regiszter)
- Fut, nem toboroz
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 80 (tervezett)
- Első benyújtás
- 2023. márc. 17.
- Kezdés
- 2023. ápr. 30.
- Elsődleges befejezés
- 2026. júl. 30.
- Fő szponzor
- Prof. Massimo Filippi
- Betegségek
- Parkinson-kór
- NCT-szám
- NCT05799690
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó
- Tervezett résztvevők: 80
- 2023. ápr. 30. és az elsődleges befejezés (2026. júl. 30.) között
- 2 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Más betegség
- Medical conditions or substance abuse that could interfere with cognition;
- Any major systemic, psychiatric, neurological, visual, and musculoskeletal disturbances or other causes of walking inability;
- Brain damage at routine MRI, including lacunae and extensive cerebrovascular disorders;
Egyéb
- Contraindications to undergoing MRI examination;
- Denied oral and written informed consent to study participation.
Kiket keres a vizsgálat
- 45 years ≤ age ≤ 85 years;
- Idiopathic PD according to the Movement Disorders Society (MDS) diagnostic criteria
- Hoehn \& Yahr (H\&Y) score <= 4
- PIGD phenotype
- Stable dopaminergic medication for at least 4 weeks and without any changes during the observation period (28 weeks)
- No dementia according to Litvan's criteria and Mini-Mental Status Examination score (MMSE) >= 24
- No significant tremor/involuntary movements that could determine artifacts during the MRI acquisition
- Oral and written informed consent to study participation
- sex-matched and age-matched (age range: mean age of PD years ± 15 years);
- oral and written informed consent to study participation
Életkor a regiszterben: 45 év – 85 év · Nem: nők és férfiak · Egészséges önkénteseket is fogad
Helyszínek (2)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| IRCCS San Raffaele | Milan | Olaszország | Ismeretlen állapot |
| Neurology Unit, Azienda Ospedaliera Universitaria Integrata di Verona | Verona | Olaszország | Ismeretlen állapot |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.